Document is current
Any future updates will be listed below
-
Authors
Olstad, Emilie Willoch
Nordeng, Hedvig Marie Egeland
Bjørk, Marte-Helene
Selmer, Kaja
Gervin, Kristina
-
Funding
Funding for this research was provided by:
Norwegian Research Council
- License Information
-
More Information
Article History
Received: 7 May 2025
Accepted: 6 October 2025
First Online: 7 November 2025
Declarations
:
: MHB reports advisory board honoraria or/and speaking honoraria from Pfizer, Jazz Pharmaceuticus, Angelini Pharma, AbbVie, Lundbeck and Eisai. Received biostatistical research support from Novartis unrelated to the present study; her department has received funding from valproate marked authorization holders to conduct postmarketing drug safety research outside the submitted work, and she is PI on an industry financed phase IV study of a migraine preventive drug (eptinezumab) unrelated to the drugs studied in the present work. KS has received consultant and speaker’s honoraria from Roche and OrionPharma. She also received non‐personal sponsorships from Desitin and Eisai AB in relation to organizing conferences. The other authors declare no conflicts of interest.
